Alex Mejia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex Mejia has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Scott Arthur Waldman
Thomas Jefferson University
3 shared publications Adam M. Frank
1 shared publication- Adrian Vella
Mayo Clinic
1 shared publication Alan J. Wein
1 shared publicationAlfredo Bianchi
1 shared publication- Anastasios Lymperopoulos
Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences (Pharmacology), Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328-2018, USA
1 shared publication
Latest Publications
- 22 March 2012
- Published by Wiley in Journal of Surgical Oncology
- Vol. 105 (5) , 468-474
Molecular staging individualizing cancer management
Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, ∼30% of patients who are node‐negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node‐negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy. J. Surg. Oncol. 2012; 105:468–474.
- 22 March 2012
- Published by Wiley in Journal of Surgical Oncology
- Vol. 105 (5) , 468-474
Molecular staging individualizing cancer management
Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, ∼30% of patients who are node‐negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node‐negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy. J. Surg. Oncol. 2012; 105:468–474.
- 1 January 2009
- Published by Elsevier
CONTRIBUTORS
- 1 September 2008
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 8 (5) , 571-578
Previstage™ GCC test for staging patients with colorectal cancer
The presence of tumor cells in regional lymph nodes is the most important prognostic and predictive marker in staging patients with colorectal cancer. Cancer cells in lymph nodes are associated wit...
- 1 September 2008
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 8 (5) , 571-578
Previstage™ GCC test for staging patients with colorectal cancer
The presence of tumor cells in regional lymph nodes is the most important prognostic and predictive marker in staging patients with colorectal cancer. Cancer cells in lymph nodes are associated wit...